List view / Grid view
Google has introduced an AI-powered 'co-scientist' designed to accelerate biomedical research and drug discovery by generating scientific hypotheses and identifying novel therapeutic targets.
Scientists have developed an AI algorithm capable of searching through 10 sextillion potential drug molecules, a feat previously considered impossible. This method could significantly speed up drug discovery and the development of new treatments.
Insilico Medicine’s AI-designed CDK12/13 inhibitors show promise against treatment-resistant cancers. Find out how this breakthrough could reshape cancer therapy.
In this article, Dr Raminderpal Singh explores the transformative impact of the Deepseek R1 open-source large language model on drug discovery. Its potential offers exciting opportunities for both scientists and software developers, marking a significant advancement for the life sciences community.
Researchers at the University of Virginia School of Medicine have developed computer models to create more targeted antibiotics. This approach aims to fight antibiotic resistance by focusing on specific bacteria in different parts of the body, reducing the reliance on broad-spectrum antibiotics.
Macrocycles outperform traditional therapeutics on several fronts, yet they account for just four percent of FDA-approved drugs. Colleagues Ann E Cleves and Ajay N Jain from Optibrium Ltd explain why we can expect to see this number increase in the coming years.
MIT's new open-source AI model, Boltz-1, could transform drug discovery by accurately predicting protein structures, offering global access to researchers.
AI is set to transform drug development in 2025, streamlining processes and opening new possibilities. Learn how this technology is transforming clinical trials and reshaping the pharmaceutical industry.
The 2024 Nobel Prize in Chemistry honours AI's transformative impact on protein science, with breakthroughs set to reshape drug development.
Explore the step-by-step scientific workflow behind drug discovery, from formulating hypotheses to analysing data, ensuring accurate and reliable results.
16 October 2024 | By
Ludwig Cancer Research researchers have designed and validated a computational pipeline which integrates molecular and genetic analyses.
Biolojic Design is redefining antibody therapies by creating “programmable” antibodies that intelligently target well-validated autoimmune and oncology pathways. In this Q&A, CEO and founder Yanay Ofran, PhD, describes Biolojic’s groundbreaking approach, which leverages AI and machine learning to design antibodies capable of adjusting their behaviour based on their biological environment.…
In this Q&A, Curve Therapeutic’s Chief Scientific Officer Professor Ali Tavassoli discusses how dual HIF inhibition could combat solid tumours.
Researchers highlight the need for considering biomarkers alongside other health outcomes, as well as the need for omic data standardisation.
Researchers have created dual-targeted CARs, which performed better than single-targeted CARs in both in vivo and in vitro experiments.
